Treatment of B-cell Acute Lymphoblastic Leukaemia has improved thanks to CAR-T therapies, but relapse is still very common.

Treatment of B-cell acute lymphoblastic leukemia has improved thanks to CAR T therapies, but relapse is still very common. An ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Treatment of B-cell Acute Lymphoblastic Leukaemia has been greatly improved by CAR-T therapies, but relapse is still very common. An international team has now found in animal models a new approach ...

T cells are white blood cells that are important for adaptive immunity. They have unique cell surface receptors that are generated by randomly assorting genes. These receptors allow T cells to ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

B-cell Acute Lymphoblastic Leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common childhood cancer, making up 35% of pediatric cancer cases, but it ...

Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.

Title: A TGFß-directed immune-modulatory vaccine induces T cell activation and drives antitumor activity by modulating the tumor microenvironment Abstract Number: 2257 Date and Time: Monday, April 28, ...

B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most ...